Molecular Biosystems of San Diego has received Food and Drug Administrationapproval to begin phase-one human clinical studies of FS069, thecompany's second-generation ultrasound contrast agent for myocardialperfusion imaging. MBI is the developer of
Molecular Biosystems of San Diego has received Food and Drug Administrationapproval to begin phase-one human clinical studies of FS069, thecompany's second-generation ultrasound contrast agent for myocardialperfusion imaging. MBI is the developer of Albunex, the firstultrasound contrast agent approved for marketing in the U.S (SCAN8/31/94).
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.